Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus vs Tacrolimus in Liver Transplantation
NCT02909335Phase 3Withdrawn
- Sponsor
- CHU Rennes
- Start
- Nov 2016
- Primary completion
- Nov 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of everolimus in liver transplantation (2 arms), sponsored by CHU Rennes. Primary endpoints: Worsening of renal function at week 48 and Occurrence of graft loss at week 48. Planned start Nov 2016; status: withdrawn.
02
Drugs
everolimus
03
Conditions
liver transplantation
Beyond the preview
Go deeper on NCT02909335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02909335.